Nalfon — Competitive Intelligence Brief

Nalfon (FENOPROFEN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal Anti-inflammatory Drug. Area: Immunology.

marketed Nonsteroidal Anti-inflammatory Drug Prostaglandin G/H synthase 1 Immunology Small molecule

Target snapshot

Nalfon (FENOPROFEN) — Pharmaco.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nalfon TARGET	FENOPROFEN	Pharmaco	marketed	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 1	1976-01-01
Joicela	LUMIRACOXIB	Novartis Pharmaceuticals UK Limited	marketed	lumiracoxib	Prostaglandin G/H synthase 1	2005-01-01
Etocox	ETORICOXIB		marketed	etoricoxib	Mitogen-activated protein kinase 14, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1	2002-01-01
Colazal	BALSALAZIDE	Valeant Pharms Intl	marketed	Aminosalicylate	Prostaglandin G/H synthase 1	2000-01-01
MOFEZOLAC	MOFEZOLAC		marketed	mofezolac	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1	1994-01-01
DEXIBUPROFEN	DEXIBUPROFEN		marketed	dexibuprofen	Prostaglandin G/H synthase 1	1994-01-01
(+)-Ketoprofen	DEXKETOPROFEN		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal Anti-inflammatory Drug class)

1. · 5 drugs in this class
2. Bausch Health · 1 drug in this class
3. Hisamitsu Pharmaceutical Co., Inc · 1 drug in this class
4. Pfizer · 1 drug in this class
5. Pharmaco · 1 drug in this class
6. Sun Yat-sen University · 1 drug in this class